Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

When Wizards of the Coast launched the Pokémon trading card game in North America in January 1999 — just months after Pokémon ...

It’s important to follow guidance on prostate-specific antigen screening that maximizes benefits and minimizes potential harms such as overdiagnosis and overtreatment.

A PSMA PET scan found more recurrent prostate cancer at low PSA levels than a standard scan, helping guide more potentially curative treatment decisions. A newer type of prostate cancer scan called 64 ...

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

New research appearing in the Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to ...

In a population-based cohort study, a single prostate-specific antigen (PSA) measurement in men aged 45-70 years effectively identified individuals with low risk for cancer. Men with PSA levels < 1.00 ...

Opportunistic prostate cancer screening can lead to overdiagnosis of indolent diseases and invasive procedures. A cohort study suggested that a low baseline PSA level in midlife was associated with a ...

Wolinsky is a Chicago-based medical journalist and publisher of The Active Surveillor, a Substack newsletter that covers lower-risk prostate cancer and active surveillance. In 2002, at age 55, I ...

This article was reviewed by Darragh O’Carroll, MD. PSA and Testosterone: Are They Linked? Prostate-specific antigen (PSA) is a term you’ll probably become familiar with once you start getting ...

The FDA has approved a novel diagnostic for prostate cancer that looks to improve upon the common screener for prostate-specific antigen, known as a PSA test. The IsoPSA blood test, developed by ...

PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...